Public signal · 1-minute delayed

Signal brief

Source-backed market context you can read and share without an account.

High materiality9/10

BioHarvest Wins first CDMO deal; 1H2027 production could unlock recurring revenue

Aug 11, 2026, 6:33 AM EDT1 sourcesAI-analyzed

Why it may matterVerify against the original reporting

The CDMO contract provides a clear near- to mid-term revenue stream and higher visibility into margin improvement via scale, plus a potential royalty model; market may reprice BHST on tangible revenue visibility and capex-driven optionality from VINIA and saffron programs.

AI summary

What happened, with direct paths to the underlying reporting

BioHarvest reported Q2 2026 revenue of $8.8 million, up 3.8% YoY, and unveiled a first exclusive CDMO 20-ton fragrance program. The deal targets a high-value ingredient to create recurring manufacturing revenue and royalties, while VINIA remains separately focused on cash flow and margin discipline. Guidance shifts toward CDMO scale with ongoing losses offset by stronger balance-sheet flexibility.

BioHarvest secures first CDMO manufacturing agreement for 20-ton fragrance over 2 years.
Q2 2026 revenue $8.8 million, up 3.8%; gross margin 58%; net loss improved.
2026 guidance revised: CDMO revenue $4–5 million; VINIA D2C $33–35 million; EBITDA losses persist.
Cash and equivalents rise to $16.25 million; VINIA active customers ~95,000 (July).

How to read this signal

Transparent limits for an AI-generated research aid

StockNews.AI groups source reporting, classifies the event, and measures subsequent price movement. This is informational research, not investment advice. Prices may be delayed or unavailable.